Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis B (CHB) are scarce. Therefore, this study aimed to evaluate the effect of TAF on the lipid in patients with CHB. Methods: A total of 237 TAF-treated CHB patients compared with TDF, inactive CHB, and non-hepatitis B virus (HBV)- infected control groups using propensity score matching (PSM). Results: Following PSM, each analysis was conducted on cohorts via the matching of 70:140 (TAF:TDF), 89:89 (TAF:inactive CHB), 140:560 (TAF:non-HBV infected control), and 368:1,472 (TDF:non-HBV-infected control). A significant decrease in the total cholesterol (TC) level was noted at 48 weeks in the TDF group compared to the TAF group (176.3±32.9 vs. 156.7±27.7, P<0.001) and the non-HBV-infected control group (175.0±29.5 vs. 156.2±28.3, P<0.001). However, no significant change in TC was observed in the TAF group and inactive CHB or non-HBV-infected control groups at 48 weeks. For the subgroup analyses of TAF vs. non-HBV-infected control subjects and inactive CHB patients whose detailed lipid profile information were available, no between-group differences in TC, low-density lipoprotein (LDL)-cholesterol, highdensity lipoprotein (HDL)-cholesterol, TC/HDL ratio, and LDL/HDL ratio were observed at 48 weeks. Conclusions: TDF seems to have a lipid-lowering effect compared to the non-HBV-infected control and TAF-treated groups. However, in real practice, TAF might not worsen the lipid profiles of subjects compared to non-HBV-infected controls and patients with inactive CHB.
Abstract
Background/Aims: Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis B (CHB) are scarce. Therefore, this study aimed to evaluate the effect of TAF on the lipid in patients with CHB. Methods: A total of 237 TAF-treated CHB patients compared with TDF, inactive CHB, and non-hepatitis B virus (HBV)- infected control groups using propensity score matching (PSM). Results: Following PSM, each analysis was conducted on cohorts via the matching of 70:140 (TAF:TDF), 89:89 (TAF:inactive CHB), 140:560 (TAF:non-HBV infected control), and 368:1,472 (TDF:non-HBV-infected control). A significant decrease in the total cholesterol (TC) level was noted at 48 weeks in the TDF group compared to the TAF group (176.3±32.9 vs. 156.7±27.7, P<0.001) and the non-HBV-infected control group (175.0±29.5 vs. 156.2±28.3, P<0.001). However, no significant change in TC was observed in the TAF group and inactive CHB or non-HBV-infected control groups at 48 weeks. For the subgroup analyses of TAF vs. non-HBV-infected control subjects and inactive CHB patients whose detailed lipid profile information were available, no between-group differences in TC, low-density lipoprotein (LDL)-cholesterol, highdensity lipoprotein (HDL)-cholesterol, TC/HDL ratio, and LDL/HDL ratio were observed at 48 weeks. Conclusions: TDF seems to have a lipid-lowering effect compared to the non-HBV-infected control and TAF-treated groups. However, in real practice, TAF might not worsen the lipid profiles of subjects compared to non-HBV-infected controls and patients with inactive CHB.
참고문헌 (32)
- GBD 2013 Mortality, "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013 : a systematic analysis for the Global Burden of Disease Study 2013", Lancet, 385, pp.117~171 (2015)
- Koumbi L, "Current and future antiviral drug therapies of hepatitis B chronic infection", World J Hepatol, 7, pp.1030~1040 (2015)
- Tang LSY, "Chronic hepatitis B infection : a review", JAMA, 319, pp.1802~1813 (2018)
- Marcellin P, "Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance : 8 year results from two phase 3 trials", 65th Annual Meeting of the American Association for the Study of Liver Diseases, pp.7~11 (2014), MA
- Fung S, "Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 146, pp.980~988 (2014)
- Hall AM, "Tenofovir-associated kidney toxicity in HIV-infected patients : a review of the evidence", Am J Kidney Dis, 57, pp.773~780 (2011)
- Babusis D, "Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340", Mol Pharm, 10, pp.459~466 (2013)
- Murakami E, "Implications of efficient hepatic delivery by tenofovir alafenamide(GS-7340)for hepatitis B virus therapy", Antimicrob Agents Chemother, 59, pp.3563~3569 (2015)
- Paul E Sax, "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials", The Lancet, 385(9987), pp.2606~2615 (2015), Elsevier BV[DOI]
- Chan HL, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.185~195 (2016)
- Buti M, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.196~206 (2016)
- Agarwal K, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection", J Hepatol, 68, pp.672~681 (2018)
- Cid-Silva P, "Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine", Basic Clin Pharmacol Toxicol, 124, pp.479~490 (2019)
- Shin JW, "Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir", Dig Dis Sci, 66, pp.1739~1750 (2021)
- 이은정, "2018 Guidelines for the Management of Dyslipidemia in Korea", 지질·동맥경화학회지, 8(2), pp.78~131 (2019), 한국지질동맥경화학회[DOI]
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Santos JR, "The lipid-lowering effect of tenofovir", emtricitabine : a randomized, crossover, double-blind, placebo-controlled trial, 2015, pp.61, 403~408
- Tungsiripat M, "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy : ACTG 5206", AIDS, 24, pp.1781~1784 (2010)
- Tarr PE, "Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons", Eur Heart J, 39, pp.2147~2154 (2018)
- Thompson-Paul AM, "Cardiovascular disease risk prediction in the HIV outpatient study", Clin Infect Dis, 63, pp.1508~1516 (2016)
- Huhn GD, "Atherosclerotic cardiovascular disease risk profile of tenofovir alafenamide versus tenofovir disoproxil fumarate", Open Forum Infect Dis (2019)
- Arribas JR, "Brief report : randomized, double-blind comparison of tenofovir alafenamide(TAF)vs tenofovir disoproxil fumarate(TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine(E", C, J Acquir Immune Defic Syndr, pp.2017, 75[DOI]
- Sax PE, "Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy : a randomized phase 2 study", J Acquir Immune Defic Syndr, 67, pp.52~58 (2014)
- Milinkovic A, "Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back", Aids, 33, pp.2387~2391 (2019)
- Taramasso L, "Lipid profile changings after switching from rilpivirine", tenofovir disoproxil fumarate, tenofovir alafenamide, pp.emtricitabine : different effects in patients with or without baseline hypercholesterolemia, PLoS One[DOI]
- Randell PA, "The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers", Antivir Ther, 15, pp.227~233 (2010)
- Behrens G, "Switching to tenofovir", emtricitabine from abacavir, Antivir Ther, pp.2012, 17[DOI]
- Shaheen AA, "Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers", Aliment Pharmacol Ther, 46, pp.599~604 (2017)
- Suzuki K, "Tenofovir-disoproxil-fumarate modulates lipid Metabolism via hepatic CD36", PPAR-alpha activation in hepatitis B virus infection, 2021, pp.56, 168~180
- 배종면, "Low Cholesterol is Associated with Mortality from Cardiovascular Diseases: A Dynamic Cohort Study in Korean Adults", Journal of Korean Medical Science, 27(1), pp.58~63 (2012), 대한의학회
- Kwon D, "Total cholesterol and mortality from ischemic heart disease and overall cardiovascular disease in Korean adults", Medicine(Baltimore), 98, pp.e17013~ (2019)
- Song YM, "Which cholesterol level is related to the lowest mortality in a population with low mean cholesterol level : a 6. 4-year follow-up study of 482, 472 Korean men", Am J Epidemiol, 151, pp.739~747 (2000)